CD109 expression in basal-like breast carcinoma

Pathology International

Volumn 58, Issue 5, 2008, Pages 288-294

  Hasegawa, Masaki ^a,b   Moritani, Suzuko ^b   Murakumo, Yoshiki ^a   Sato, Tomoko ^a   Hagiwara, Sumitaka ^a   Suzuki, Chikage ^a   Mii, Shinji ^a   Jijiwa, Mayumi ^a   Enomoto, Atsushi ^a   Asai, Naoya ^a   Ichihara, Shu ^b   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Basal like breast carcinoma; CD109; Estrogen receptor; Fat invasion; HER2; Progesterone receptor

Indexed keywords

CD109 ANTIGEN; CELL SURFACE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL; LYMPHOCYTE ANTIGEN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BASAL LIKE BREAST CARCINOMA; BREAST CARCINOMA; CANCER CLASSIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MYOEPITHELIUM CELL; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, NEOPLASM; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 42549093126     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2008.02225.x     Document Type: Article

References (36)

1. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000 406 : 747 52.
2. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 98 : 10 69 74.
3. Sørlie T, Wang Y, Xiao C et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: Gene expression analyses across three different platforms. BMC Genomics 2006 7 : 127.
4. Tsuda H, Takarabe T, Hasegawa T et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999 30 : 1134 9.
5. Banerjee S, Reis-Filho JS, Ashley S et al. Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. J Clin Pathol 2006 59 : 729 35.
6. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007 109 : 25 32.
7. Purkis PE, Steel JB, Mackenzie IC et al. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990 97 : 39 50.
8. Wetzels RH, Kuijpers HJ, Lane EB et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991 138 : 751 63.
9. Heatley M, Maxwell P, Whiteside C et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 1995 48 : 26 32.
10. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004 203 : 661 71.
11. Lin M, Sutherland DR, Horsfall W et al. Cell surface antigen CD109 is a novel member of the a2 macroglobulin/C3,C4,C5 family of thioester-containing proteins. Blood 2002 99 : 1683 91.
12. Murray LJ, Bruno E, Uchida N et al. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 1999 27 : 1282 94.
13. Finnson KW, Tam BY, Liu K et al. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J 2006 20 : 1525 7.
14. Hashimoto M, Ichihara M, Watanabe T et al. Expression of CD109 in human cancer. Oncogene 2004 23 : 3716 20.
15. Asai N, Jijiwa M, Enomoto A et al. RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int 2006 56 : 164 72.
16. Zhang JM, Hashimoto M, Kawai K et al. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 2005 55 : 165 9.
17. Sato T, Murakumo Y, Hagiwara S et al. High-level of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 2007 57 : 719 24.
18. Hasegawa M, Hagiwara S, Sato T et al. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 2007 57 : 245 50.
19. Jacobs TW, Gown AM, Yaziji H et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999 17 : 1983 7.
20. Stefanou D, Batistatou A, Nonni A et al. p63 expression in benign and malignant breast lesions. Histol Histopathol 2004 19 : 465 71.
21. Matos I, Dufloth R, Alvarenga M et al. p63, cytokeratin 5, and P-cadherin: Three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005 447 : 688 94.
22. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006 19 : 264 71.
23. Coyne JD, Dervan PA, Barr L. High-grade carcinomas of the breast showing patterns of mixed ductal and myoepithelial differentiation (including myoepithelial cell-rich carcinoma of the breast). Histopathology 2004 44 : 580 84.
24. Bocker W, Bier B, Freytag G et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II. Epitheliosis and ductal carcinoma in situ. Virchows Arch A Pathol Anat Histopathol 1992 421 : 323 30.
25. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma. Clin Cancer Res 2004 10 : 5367 74.
26. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: A possible precursor to invasive basal-like breast cancer. Mod Pathol 2006 19 : 617 21.
27. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004 91 : 1532 42.
28. Foulkes WD, Brunet JS, Stefansson IM et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004 64 : 830 35.
29. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006 25 : 5846 53.
30. Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006 49 : 22 34.
31. Livasy CA, Perou CM, Karaca G et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007 38 : 197 204.
32. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004 17 : 646 52.
33. Grenier J, Soria JC, Mathieu MC et al. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res 2007 27 : 547 55.
34. Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007 9 : R24.
35. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: An immunohistochemical and gene amplification study. Am J Surg Pathol 2007 31 : 501 8.
36. Reis-Filho JS, Milanezi F, Paredes J et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003 11 : 1 8.